Adma Biologics Inc (ADMA) concluded trading on Thursday at a closing price of $18.4, with 4.47 million shares of worth about $82.2 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 5.75% during that period and on June 26, 2025 the price saw a gain of about 4.55%. Currently the company’s common shares owned by public are about 238.53M shares, out of which, 230.52M shares are available for trading.
Stock saw a price change of 1.49% in past 5 days and over the past one month there was a price change of -7.49%. Year-to-date (YTD), ADMA shares are showing a performance of 67.12% which increased to 7.29% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $10.21 but also hit the highest price of $25.67 during that period. The average intraday trading volume for Adma Biologics Inc shares is 3.52 million. The stock is currently trading -6.66% below its 20-day simple moving average (SMA20), while that difference is down -11.21% for SMA50 and it goes to -2.43% lower than SMA200.
Adma Biologics Inc (NASDAQ: ADMA) currently have 238.53M outstanding shares and institutions hold larger chunk of about 86.39% of that.
The stock has a current market capitalization of $4.39B and its 3Y-monthly beta is at 0.45. PE ratio of stock for trailing 12 months is 21.80, while it has posted earnings per share of $0.84 in the same period. Its PEG reads 0.55 and has Quick Ratio of 3.36 while making debt-to-equity ratio of 0.22. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ADMA, volatility over the week remained 3.48% while standing at 4.18% over the month.
Stock’s fiscal year EPS is expected to rise by 27.15% while it is estimated to increase by 51.61% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Raymond James on July 19, 2023 offering a Strong buy rating for the stock and assigned a target price of $5 to it. Coverage by Mizuho stated Adma Biologics Inc (ADMA) stock as a Buy in their note to investors on October 13, 2022, suggesting a price target of $5 for the stock. On November 11, 2021, Raymond James Upgrade their recommendations, while on November 09, 2021, Cantor Fitzgerald Initiated their ratings for the stock with a price target of $4.50. Stock get a Buy rating from Jefferies on June 04, 2019.
